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1. Introduction 
Coronary artery disease (CAD) is the foremost cause of morbidity in the worlds 
industrialised nations. Consequently our ability in understanding the treatments available 
and the mechanisms of their success/failure is of particular importance as we strive to 
improve procedural success rates through the evolution of existing and the innovation of 
new interventional technologies. Today, the gold standard for treating CAD is to deploy a 
drug eluting stent (DES) in the blocked artery to first restore luminal blood flow and second 
to resist the body’s tendency to block the artery once more through its overly aggressive 
healing response known as restenosis. Intrinsically, the understanding of mass transport is 
elemental to all aspects of DES design from the type of drug used and the polymer release 
characteristics to the shape and thickness of the stent struts. Design optimisation of DES is 
vital to achieving increases in procedural success rates as the technology evolves, as is the 
case for its newest embodiment, the biodegradable DES. 
This chapter addresses issues fundamental to drug mass transport from DES, starting with 
an overview of CAD and associated interventional procedures. DES mass transport theory is 
then presented and followed by accounts of mass transport problem classifications 
employed by researchers under a number of deployment scenarios. The importance of 
experimental mass transport validation is highlighted and a computational investigation is 
developed to demonstrate how differences in DES deployment conditions alter drug 
concentrations in the artery wall. 
2. Coronary artery disease 
Atherosclerosis is a degenerative disease that affects coronary, carotid and other peripheral 
arteries in the body. Disease formation can occur as early as childhood with the 
development of fatty streaks within the artery wall. As the aging process progresses, these 
fatty streaks accumulate to become larger lipid deposits within the artery. This gradual 
propagation of plaque can be detrimental to the smooth operation of the vasculature. 
Occlusions ensuing from aggressive atherosclerotic plaque progression can often culminate 
in an ischemic attack, such as a stroke or a heart attack. CAD pertains to a blockage or 
narrowing of the coronary arteries that provide oxygen and nutrients vital to the smooth 
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operation of the heart muscle. Once identified as such, there are a number of interventional 
procedures available to the cardiologist but the successful emergence of stents, and more 
recently DES, has seen them become the preferred choice of treatment for CAD, so much so 
that by the beginning of 2006 more than 8 out of 10 coronary stents were DES (Head et al., 
2007) at a cost of between $4 and $5 billion annually (Kaul et al., 2007). 
CAD has been intrinsically linked to atherosclerosis since the early 20th century (Chen et al., 
2005) and refers to the localisation of disease within the coronary arteries. It is generally 
asymptomatic and those afflicted often only realise they have the condition when it 
manifests itself in the form of a heart attack. For this reason CAD is the foremost cause of 
mortality in the world’s industrialised nations (Khakpour &Vafai, 2008). CAD alone is 
reportedly responsible for approximately 700,000 deaths in the United States of America 
annually (Kaazempur-Mofrad et al., 2005). Lifestyle choices made by an individual, such as 
not smoking, regular exercise and a balanced diet, have been shown to influence CAD 
development but it is the concentration of lipid rich cholesterol in the blood that is 
considered the most important factor (Sun et al., 2006). 
2.1 Traditional interventional procedures 
Numerous ways exist to alleviate a stenosis in a coronary artery once detected. The first 
such interventional procedure commonly practiced was coronary artery bypass graft 
(CABG) surgery. CABG surgery was successfully performed first by Robert H. Goetz and 
his team in 1960 at the Albert Einstein College of Medicine (Haller & Olearchyk, 2002). Prior 
to surgery an angiogram is conducted in order to locate the occlusion within the artery, after 
which a median sternotomy is performed, which exposes the heart and enables the blocked 
coronary arteries to be bypassed. This procedure is traumatic for the patient with extensive 
recovery times and significant scarring to the chest. Furthermore, the long term patency 
rates of these grafts were moderate and several efforts have been made in vain to optimise 
downstream graft artery junctions. Despite this, CABG remained the gold standard in the 
treatment of CAD until 1977 when Andreas Gruntzig first performed percutaneous 
transluminal coronary angioplasty (PTCA) (Kukreja et al., 2008). CABG is a procedure still 
used today as not every patient is eligible for minimally invasive surgeries such as PTCA 
due to highly tortuous or extensively blocked arteries. 
Initially PTCA was welcomed by the clinical community due to its minimally invasive 
approach to arterial stenosis alleviation. A balloon catheter is introduced through an 
incision in the femoral artery and is manoeuvred through the vasculature until it reaches the 
stenosis. Once inflated, the balloon pushes the plaque back against the artery wall and 
enables blood flow to recommence after it has been deflated. The initial success of PTCA 
was short lived as investigators soon discovered that a substantial percentage of patients, 
reported to be anywhere between 30% and 60%, experienced recurrent ischemia due to the 
re-blocking of the artery (restenosis) within the first 6 months. This was attributed to 
mechanical injury caused by over dilating a device within the vessel (Head et al., 2007). 
The next major advance in the field of minimally invasive interventional cardiology came in 
the early 1990’s with the advent of the coronary artery stent (CAS). Prior to surgery a 
cylindrical metallic scaffold, or stent, is placed on the end of an existing balloon catheter and 
deployed in the same way as traditional PTCA. Initially, these stents were mounted on the 
balloon catheter by the physician, however, in more recent times the manufacturers supply 
the catheters with a stent already in situ. After deployment the stent remains within the 
artery in an attempt to retain arterial patency. CAS reduced failure rates tobetween 10% and 
40% (Duraiswamy et al., 2007; Mongrain et al., 2007) through the elimination of elastic recoil 
and negative remodelling of the artery associated with PTCA (Costa and Simon, 2005). 
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2.2 Restenosis and the advent of the drug eluting stent era 
Restenosis can best be described as an overly aggressive inflammatory healing response in 
the artery wall due to the mechanical injury inflicted by balloon/stent expansion. It can be 
quantified by the reduction of lumen size after an intravascular interventional procedure. 
The development of restenosis can be described by three processes after PTCA; 1) elastic 
recoil, 2) arterial negative remodelling and 3) neointimal hyperplasia (Rajagopal&Rockson, 
2003). Elastic recoil can occur within an hour of PTCA and is due to passive recoil of the 
elastic medial layer of the artery. Arterial remodelling on the other hand can be both 
positive (vessel enlargement) or negative (vessel shrinking) and is characterised as such by a 
change in vascular dimension. Investigators report contrasting views on the mechanisms 
behind negative remodelling but whatever the underlying pathology behind vascular 
remodelling, it is believed to be virtually eliminated when angioplasty is used in 
conjunction with a stent. 
Over inflation of a balloon catheter can result in the fracture of atherosclerotic plaque and in 
some cases can cause partial fracture of the artery wall (Schwartz et al., 2004). The same 
crushing/fracturing effect is witnessed when a stent is used in conjunction with an over 
inflated balloon. However, a stent can also cause excessive injury by penetrating the media 
which in turn increases neointimal formation. In some extreme cases stents have been 
known to penetrate as deep as the adventitial layer of the artery (Costa and Simon, 2005). 
The introduction of the DES to market has gone someway to alleviating the issue of arterial 
restenosis and excessive vessel injury via stent expansion. Variations of anti-restenotic drugs 
have been used to coat the stent in order to prevent post-operative in stent restenosis (ISR) 
and these modern stents can have strut profiles in the order of 80µm which would minimise 
the possibility of adverse artery wall penetration. 
It is generally accepted that one of the main causes of restenosis following BMS implantation 
is SMC proliferation from the medial artery layer to the injured site. Attempts at systemic 
drug delivery to inhibit restenosis after stenting failed because effective dosing levels had a 
toxic effect and could not be tolerated by the patients (Waksman, 2002). Therefore the 
concept of local drug delivery was developed to redress the issue through the application of 
a drug eluting coating to the stent platform. This enables site specific local delivery of drugs 
that can be applied to the injured vessel at the exact location and time that damage occurs.  
The anti-restenotic coating on DES inhibits the formation of neointimal hyperplasia via 
suppression of the inflammatory reaction, platelet activation and SMC proliferation, curbing 
the overly aggressive healing response. Most of the early drugs explored originally were 
those used as agents for anti-transplant rejection or immunosuppressive drugs (van der 
Hoeven et al., 2004).  
In April 2003 the first DES to gain commercial approval from the Food and Drug 
Administration (FDA) in the United States was the Cypher stent, which was developed by 
Cordis Corporation (Miami, FL. USA). The drug used on the Cypher stent is called 
sirolimus. Boston Scientific’s (Natik, MA. USA) TAXUS family of stents were the second 
DES platform approved by the FDA in March of the following year. The drug employed on 
the TAXUS stent is called paclitaxel (Venkatraman and Boey, 2007).The first generation DES 
had a profound effect on reducing restenosis rates compared to bare metal stent (BMS) 
models. Clinical trials carried out on the Cypher stent (SIRIUS-1) showed restenosis rates of 
8.9% after 8 months compared to 36.6% for BMS in the same study. Likewise the TAXUS IV 
trials heralded a dramatic reduction in restenosis rates when compared to BMS after 9 
months, 7.9% versus 26.6% respectively (Venkatraman and Boey, 2007). 
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A successful DES procedure is defined by its ability to transport the right amount of an 
appropriate drug within the correct timeframe that will ultimately deem the operation a 
success through the prevention of ISR. There are aspects of the performance of a DES that 
can be controlled by the manufacturer which has led to considerable reductions in the 
instances of ISR, such as the type of drug used and the characteristics of the coating that the 
drug is stored in. Even the stent shape, thickness and width of the struts can all influence the 
manner in which the drug is transported. However, the ability for drug uptake within the 
artery wall is also governed by its interaction with the patient specific arterial environment, 
making it near impossible to completely eradicate ISR. The degree of initial stenosis, the 
presence of luminal and abluminal thrombus on the stent and even the advent of re-
endothelialisation will all contribute to the DES ability to transport drugs throughout the 
artery wall.  
3. Mass transport theory of drug eluting stents 
Mass transport refers to the movement of mass, i.e. the species of interest which is drugs in the 
case of a DES, within a defined system. This transport of species may be provoked by 
concentration gradients between two points, but quite often in systems, especially in the 
vasculature, overpowering complex flow dynamics will ultimately be responsible for the mass 
transport outcome. In the absence of a free flowing system the presence of these concentration 
gradients induces diffusion, e.g. between the DES and the artery wall. Mass transport can be 
broken up into two types within the human vasculature. Firstly blood side mass transport 
(BSMT) refers to species transport within the vessel lumen and is subject to the 
haemodynamics therein. Often evanescent due to haemodynamic washout, BSMT can only be 
effective in transporting anti-proliferative agents to the wall in regions of high recirculation. 
The second, and most important, mode of mass transport is in relation to transport within 
the wall of the artery, referred to as wall side mass transport (WSMT). Along with the 
properties of the species being transported within the artery wall, WSMT depends on the 
structural condition of the wall itself, whereby a damaged intimal layer could facilitate 
accelerated mass transport through to the medial layer. WSMT can be governed by two 
transport forces, a pressure driven convective force and a diffusive force. The Peclet number 
(Pe), see equation 11, is a dimensionless parameter that can be used to determine the relative 
influences of these two forces. A small Pe (i.e. Pe<1) is representative of transport which is 
dominated by diffusion, while a higher Pe (i.e. Pe>1) indicates convection dominated mass 
transport (Friedman, 2008). 
3.1 Governing equations 
Computational Fluid Dynamics has emerged as one of the most powerful numerical tools 
for engineers, scientists and mathematicians alike. Its foundations are based on theoretical 
analysis drawn from experimental observations over various branches of physics. The 
starting point for any computational analysis is the appropriate allocation of the governing 
equations. These equations are then substituted with equivalent numerical descriptions that 
are then solved using appropriate mathematical techniques. There are a number of 
numerical techniques available that will return a solution to a specified problem. Two of the 
more popular methods are the Finite Volume Method and the Finite Element Method. The 
assumptions generally applied when modelling fluid flow problems of this nature are as 
follows: 
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• The flow is incompressible and isothermal 
• The fluid is Newtonian and possesses constant physical properties 
• Flow is considered to be laminar 
3.1.1 Conservation of mass: Continuity equation 
The conservation of mass is a form of continuity equation which states the net mass flow 
into a control volume is equal to the rate at which mass leaves the control volume. That is 
providing there are no sinks or sources within the control volume. The differential form of 
the equation can be obtained by simply considering the flow into and out of elementary 
control volume. For the Cartesian co-ordinate system, having coordinates x, y, z referenced 
to a stationary frame with the corresponding velocity components u, v, w (m/s), the 
continuity equation can be written as: 
 
( ) ( ) ( )
0
u v w
t x y z
ρ ρ ρρ ∂ ∂ ∂∂ + + + =∂ ∂ ∂ ∂   (1) 
Where the density (ρ, kg/m3) is a constant, as is the case of incompressible flow, this reduces 
further to a volume continuity equation. 
 0
u v w
x y z
∂ ∂ ∂+ + =∂ ∂ ∂  (2) 
3.1.2 Balance of momentum: Navier-Stokes Equations 
The balance of momentum is derived from Newton’s second law of motion, which states 
that the rate of change of momentum of a fluid particle is equal to the sum of the forces on 
the particle. The Navier-Stokes Equations describe the full three dimensional, viscous nature 
of fluid motion in a control system: 
2 2 2
2 2 2
u P u u u
t x x y z
ρ μ ⎛ ⎞∂ ∂ ∂ ∂ ∂= − + + +⎜ ⎟⎜ ⎟∂ ∂ ∂ ∂ ∂⎝ ⎠
  
 
2 2 2
2 2 2
v P v v v
t y x y z
ρ μ ⎛ ⎞∂ ∂ ∂ ∂ ∂= − + + +⎜ ⎟⎜ ⎟∂ ∂ ∂ ∂ ∂⎝ ⎠
 (3) 
2 2 2
2 2 2
w P w w w
t z x y z
ρ μ ⎛ ⎞∂ ∂ ∂ ∂ ∂= − + + +⎜ ⎟⎜ ⎟∂ ∂ ∂ ∂ ∂⎝ ⎠
  
Where µ(Pa s) is dynamic viscosity and P(Pa) is pressure. Due to the porous nature of the 
artery wall, flow within it must consider the influence of the tissues permeability. Therefore 
the flow within the wall is assumed to follow Darcy’s law and is demonstrated (in the x 
direction) by the inclusion of the permeability term in equation 4, where K(m2) is the 
permeability of the arterial tissue. 
 
2 2 2
2 2 2
  u P u u u u
t x Kx y z
μρ μ ⎛ ⎞∂ ∂ ∂ ∂ ∂ ⎛ ⎞= − + + + −⎜ ⎟ ⎜ ⎟⎜ ⎟∂ ∂ ∂ ∂ ∂ ⎝ ⎠⎝ ⎠
 (4) 
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3.1.3 Fick’s laws of diffusion 
Species transport via diffusion is a process driven by concentration gradients between two 
locations. Fick’s first law can be used to describe the diffusional flux (Jx, mol/m2s) of such 
species, shown in 1D in equation 5, where D(m2/s) is diffusivity and c is concentration 
(mol/m3): 
 x
c
J D
x
∂= − ∂   (5) 
The negative term in equation 5 indicates that the flux is positive in the presence of a 
negative concentration gradient. Biological mass transport often requires the application of a 
time-dependent mass transport process that can predict variations in concentration over 
time. Fick’s second law (equation 6) can provide such a relationship and is defined here in 
one dimension: 
 
2
2 
c c
D
t x
∂ ∂=∂ ∂
   (6) 
3.1.4 Conservation of species: Convection-diffusion equation 
The addition of a convective term, equal to the product of the fluid velocity and the local 
concentration, to equation 6 demonstrates the 3D transport of species in a flowing solution. 
This is known as the convection-diffusion equation. 
 
2 2 2
2 2 2
c c c c c c c
u v w D
t x y z x y w
⎛ ⎞∂ ∂ ∂ ∂ ∂ ∂ ∂+ + + = + +⎜ ⎟⎜ ⎟∂ ∂ ∂ ∂ ∂ ∂ ∂⎝ ⎠
 (7) 
3.1.5 Ratio of convective to diffusive forces 
The Peclet number (Pe) is a dimensionless number that determines the relative 
contribution of convective and diffusive forces to species transport within a defined 
system. It can be defined as a product of the Reynolds number (Re) and the Schmidt 
number (Sc). 
 .Pe Re Sc=  (8) 
The Reynolds number is a non-dimensional parameter concerning fluid forces due to 
viscosity and inertia and is essentially used to determine whether a flow is laminar, 
transitional or turbulent in nature. For example a Reynolds number of approximately 90 can 
be obtained for a mean arterial velocity (u) of 0.1m/s in an artery with a diameter (a) of 
3mm. When considering transmural flow through the porous artery wall the value awould 
represent the thickness of the porous wall. 
 
ua
Re
ρ
μ=   (9) 
The Schmidt number (Sc) is defined as the ratio of kinematic viscosity (ǖ, m2/s) to diffusivity 
(D). 
 
v
Sc
D D
μ
ρ= =   (10) 
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Substituting equations 9 and 10 into 8 describes how convective and diffusive forces can 
influence the outcome of the Peclet number. 
 uaPe
D
=  (11) 
3.1.6 Diffusion in porous materials 
When considering diffusion in a fluid saturated porous media, as is the case with the artery 
wall, diffusion takes place over a tortuous path. Because these pores are not straight, the 
distance over which diffusion takes place becomes effectively longer than for a homogenous 
material of the same thickness. The effective diffusivity (Deff) can therefore be deduced by 
considering the impact of the materials structure on the species free diffusivity (Dfree). The 
effective diffusivity of a porous material is a function of its porosity (ε) and tortuosity (Ǖ). 
 eff freeD D
ε
τ=  (12) 
One of the more common ways to determine the free diffusivity of a species in a solvent is to 
use the Stokes-Einstein equation (13), where k(J/K) is the Boltzmann constant, T(K) is 
temperature and R(m) is the radius of the solute. For the purpose of diffusion in the artery 
wall, this solvent is considered to be plasma. 
 
6
free
kT
D
Rπμ=  (13) 
The radius of the solute can be calculated from equation 14 assuming that the particle is 
spherical in shape, where M(Kg/mol) is the solute molecular weight and Na(mol-1) is 
Avogadro’s number. 
 
1
33
4
M
R
Naπρ
⎛ ⎞= ⎜ ⎟⎝ ⎠
  (14) 
The structure of the porous medium is defined by the tortuosity(Ǖ) of its porous network 
(15) and by the porosity(ε) (16) of the material itself. 
 
L
X
τ =  (15) 
Where L = pore path length and X = distance between beginning and end of the pore path. 
 
 
 
PoreVolume
TotalVolume
ε =  (16) 
4. Problem classification 
In reality the classification of problems of this nature are inherently patient specific and as 
such no one representation of the problem is correct. However, there are innate similarities 
between patients. Blood flow within the vasculature is a highly complex 3D process to 
model given the pulsatile nature of arterial haemodynamics. Coupled with this pulsatile 
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process, the coronary arteries are situated on the surface of the heart and as such are subject 
to cyclic motion due to the beating of the organ. Therefore the modelling of drug transport 
from a DES in these arteries is multifaceted in nature, comprising of both luminal and artery 
wall mass transport, the latter of which may also be subject to a reaction giving that some 
drug may bind to the arterial tissue. The introduction of a multi-layered artery wall to the 
model increases the complexity of the domain even further. So to what extent does one go to 
when modelling DES mass transport? 
Comprehensively modelling the behaviour of a DES computationally over a given time period 
would require the application of the following in vivo conditions experience by the device. 
• The DES would have to be placed in multi-layered diseased artery. 
• Both BSMT and WSMT would have to be considered. 
• The real time occurrence of thrombus formation and re-endothelialisation under 
pulsating flow conditions would need to be modelled. 
• The structural deformation of the artery wall due to DES deployment would need to be 
taken into account. 
• Also the movement of the vessel in space due to its location on the surface of the 
beating heart and how this may alter depending on the extent of the patient’s physical 
activeness would have to be considered. 
In light of the computational requirements to undertake such a model it is possible, and 
almost necessary, to make certain assumptions in order to simplify both BSMT and WSMT 
models whilst retaining enough detail of the actual model to draw relevant conclusions 
from the analysis. 
The implementation of an arterial pulse and a beating heart are neglected by most 
researchers. Often the artery is modelled as rigid in space in order to analyse mass transport 
post DES deployment. This is an effective assumption but one must consider the 
deformation of the artery wall due to the dynamic expansion of the stent, as this can have an 
impact on the mass transport outcome due to the porous nature of the wall and the 
compression it incurs upon stent expansion. As for the application of laminar blood flow, it 
can be seen that the majority of drug that enters the artery wall from the DES does so via 
physical contact with the wall and the drugs emanating from the areas of the stent exposed 
to flow, be it laminar or pulsatile, are predominantly carried downstream. 
4.1 Artery wall classification 
Arteries transport oxygen rich blood around the body providing essential nutrients to vital 
organs. The artery wall consists of a complex multilayer porous substructure with an 
interstitial phase comprising predominantly of plasma. In a healthy artery this substructure 
(Figure 1) is comprised of three concentric layers; the tunica intima, the tunica media and 
the tunica adventitia. The tunica intima is the innermost layer, consisting of a single layer of 
endothelial cells and a subendothelial layer mainly consisting of delicate connective tissues 
and collagen fibres. The outer boundary of the tunica intima is surrounded by an elastic 
tissue with fenestral pores known as the internal elastic lamina (IEL). The medial layer 
consists primarily of concentric sheets of smooth muscle cells (SMC) within a loose 
connective tissue framework. This configuration of SMC enables the artery wall to contract 
and relax. The tunica media and the tunica adventitia are separated by another thin band of 
elastic fibres known as the external elastic lamina (EEL). The outermost layer of the artery, 
the tunica adventitia, is comprised of connective tissue fibres and some capillaries. These 
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fibres blend into the surrounding connective tissues and aid in stabilising the arteries within 
the body (Khakpour and Vafai, 2007). 
The target layer for the anti-restenotic drugs is the tunica media, where the SMC reside, and 
quite often computational studies will consider just this arterial layer not only because of 
this fact but also due to the possible erosion of the tunica intima upon stent deployment. 
Regardless of the level of complexity modelled, the artery wall is porous in composition and 
drug transport is facilitated through the surrounding plasma not only via diffusion but there 
is also the presence of a transmural velocity due to a pressure gradient observed across the 
artery wall. However, the presence of arterial plaque will reduce the magnitude of this 
transmural velocity and can even stem it altogether. As DES are deployed in highly 
occluded arteries it is reasonable to reduce the complexity of the problem by neglecting 
convection in the wall. Equation 12 gives us an indication of how arterial properties such as 
porosity, tortuosity and free diffusivity can influence the transport of drugs within the 
respective artery wall layers. The compression of these layers will alter these properties 
which in turn may inhibit the transport of species as governed by the mass transport 
equations. The compression of a porous structure not only reduces the materials porosity 
but it results in the creation of a more arduous pore path over which mass transport would 
normally occur. The combination of a reduced porosity with an increased tortuosity, when 
the artery wall has been compressed, has a net effect of reducing the effective diffusivity 
thus hindering mass transport within the vessel. 
 
 
Fig. 1. Illustration of the cross-sectional structure of a healthy artery wall. 
4.2 Influence of thrombus 
Hwang et al. (2005) were among the first to explore the influence of thrombus height, width 
and type on the arterial drug uptake. Stents can be deployed at sites of thrombus and after 
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implantation a clot will inevitably develop once the struts become covered with plasma 
proteins. In most cases this will not be angiographically present or clinically evident but 
even a fine layer of clotting blood deposited on the surface of the DES can alter drug 
distribution within the wall. The presence of clot alters the local environment of the stent 
strut and the physiological transport forces that regulate arterial uptake and retention. 
Balakrishnan et al.(2008) reported that drug eluting stents clot at a rate of 0.6% each year 
after implantation for up to 3 years. Strut position within a clot also has a major influence on 
the arterial uptake. The greater the volume of clot covering the strut, and the closer the strut 
is to the wall, creates improved conditions for greater drug delivery. Hwang et al. (2005) 
discovered that in this configuration concentration distribution in the wall can be 30 fold 
higher than situations where no clot is present. Similarly thrombus or plaque between the 
strut and the artery wall act as a buffer layer and reduce wall concentrations. Clot 
diffusivities higher than that of the artery wall will result in drug transfer to the blood at a 
rate faster than can be absorbed by the wall. Clots with diffusivities equal to or lower than 
the artery wall can transport drugs to the wall at a rate where the wall can effectively absorb 
the drugs, thus reducing drug loss to the bloodstream. 
 
 
Fig. 2. An illustration of how Focal (A) and Diffuse (B) thrombus, surrounding a DES strut, 
contribute to drug mass transport within the artery wall. 
In 2008, Balakrishnan et al. demonstrated how variations in thrombus size and distribution 
contribute to fluctuating arterial drug intensities (Figure 2). Their simulations indicate that 
thrombus cannot influence the slow rate of drug release from the stent because the polymer 
resistance to drug transport is significantly greater than that of the thrombus, which is 
consistent with in vivo experimental drug release. Focal thrombus, with a thickness of 
0.1mm, increased peak average drug concentration by 80%. Greater clot formation between 
stent struts will also have an effect on arterial concentrations because once the species is 
transported within the clot it effectively increases the surface area from which the artery 
wall can absorb drugs. The formation of this interstrut thrombus, described as diffuse 
thrombus, acts as a shield from drug washout and culminates in an increase in arterial 
concentration by up to 3.5-fold. 
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The variability of thrombus can have a major impact on arterial drug concentrations. It can 
aid in drug uptake and retention within the wall when it covers the stent, but too much 
thrombus will effectively block the artery, thus creating a problem that the DES aimed to 
alleviate. Also it can act as a barrier in preventing drugs from reaching the wall when it is 
located between the strut and the wall. The likely scenario following DES implantation 
within the vasculature is that at some location along the length of the stent each of these 
situations will be present. In addition to issues arising from the development of thrombus, 
the presence of plaque in a freshly stented artery will have a similar effect on mass transport 
but does so immediately upon implantation, as opposed to thrombus which develops with 
time. The initial presence of the plaque coupled with the time dependent formation of 
thrombus, and even the occurrence of re-endothelialisation, would create a realistic stenting 
scenario if modelled but the volume and formation of these will be different for each person. 
So to what extent does one model this? 
4.3 Polymer and drug characterisation 
Stent coatings play a vital role in the regulation of drug release from the stent. Careful 
consideration must be observed when allocating a polymer as a drug carrier for a DES. If the 
polymer is not biocompatible an inflammatory response ensues. It has been shown that the 
development of neointimal hyperplasia can be doubled when certain polymer 
configurations are used compared with a controlled substance (Granada et al., 2003). Each 
biologically viable polymer must be able to endure the stresses exerted when stents are 
deployed, resist cracking, peeling and maintain their physiochemical properties after 
sterilisation. Drug release rates can be altered with the addition of an extra layer of polymer 
coating to modulate between slow and fast release formulations. This adds an extra degree 
of complexity when designing functional DES and indeed analysing them computationally. 
Sirolimus, everolimus and paclitaxel were among the first anti-restenotic agents used in 
DES. Sirolimus, or rapamycin, is a naturally occurring macrocyclic lactone. It was approved 
by the FDA in 1999 for the prophylaxis of renal transplant rejection because of its potent 
immunosuppressive properties (Costa & Simon, 2005). Essentially sirolimus inhibits the 
activation of multiple kinases, associated with cell proliferation, resulting in the cessation of 
cellular division between the G1/S phases and is said to be cytostatic in nature (Burt & 
Hunter, 2006). Everolimus is an analogue of the sirolimus immunosuppressant which binds 
to cytosolic immunophillin FKBP12. It is very similar to sirolimus in that it prevents the 
cellular division between the G1/S phases of the cell cycle therefore inhibiting SMC 
proliferation (Stone et al., 2008). 
Paclitaxel is a naturally occurring drug that was originally extracted from the pacific yew 
tree Taxusbrevifolia. It was initially used to treat several types of cancer such as breast and 
ovarian cancer (Tanabe et al., 2004). Like sirolimus and everolimus, paclitaxel is effective in 
reducing restenosis but it does so in a manner that results in cell death, suggesting that it 
works through a cytotoxic mechanism (Parry et al., 2005). Paclitaxel achieves its anti-
proliferative effects by binding to aminoterminus β-tubulin thus disrupting microtubule 
dynamics. This results in the arrest of cells at the M stage and even G2 stages of the cell 
cycle, leading to cell death (Hara et al., 2006). Due to its lipophilic properties paclitaxel has 
been known to be loaded directly onto stents without a polymer coating but there could be 
potential implications with regards to a lack of controlled release (Burt & Hunter, 2006). 
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4.4 DES problem design and deployment 
This problem can be approached in one of two ways, do you a) want to compare the mass 
transport capabilities between different stent designs or b) want to analyse arterial mass 
transport for a single stent design under various stenting and artery wall conditions. The 
latter of which is of more initial interest because a comprehensive understanding of a 
multifaceted mass transport study with a generic stent design will give a greater 
understanding of the interactions between drug/polymer characteristics and the arterial 
condition. Once these interactions are better understood the researcher can revert to 
comparing stent designs for a predetermined deployment configuration. 
The main goal of a DES is to prevent the onslaught of arterial restenosis, which occurs in 
part due to damage inflicted on the artery during stent deployment. However, researchers 
to date have generally neglected the artery wall damage induced and its influence on mass 
transport. An exploratory DES mass transport computational study, even if it is only 2D 
modelling, should consider both cause and effect. A stent should not just be placed flush 
with the artery wall, there is going to be some wall indentation and intimal damage, the 
extent of which is a study onto itself. To this end the resulting artery wall compression will 
alter the effect that is the transport of the anti-restenotic drugs throughout the artery wall. 
Stent design and drug/polymer properties, although of significant importance, should be a 
secondary consideration until these fundamental issues have been addressed. 
5. Typical computational boundary conditions for DES models 
Once the governing equations have been applied to the model domain the boundary 
conditions need to be allocated. Often with biological modelling it is necessary to make 
assumptions when applying boundary conditions. For example treating the artery wall as 
rigid (Mongrain et al., 2007; Devereux, 2005; Kaazempur-Mofrad and Ethier, 2001) or 
assuming that mass transport within the wall is modulated solely by diffusion 
(Balakrishnan et al., 2008, 2007, 2005; Mongrain et al., 2007, 2005) are two examples of ways 
commonly employed to simplify what is in reality a very complex problem. However, as 
previously mentioned the fundamental in vivo issues should be taken into account as much 
as possible when applying such simplifications. 
5.1 Application of momentum boundary conditions 
5.1.1 Inlet: Velocity 
The heart is a muscular organ that undergoes repetitive contraction and relaxation of its 
walls in order to propel blood through the circulatory system. Coupled with the complex 
geometry of the coronary arteries, the pulsating blood velocity profile is an integral part in 
the mass transport behaviour of blood borne species. However, when considering the 
transport of drugs from a DES a common assumption to make is the presence of a steady 
fully developed flow profile within the lumen (Balakrishnan et al., 2008, 2007, 2005; 
Mongrain et al., 2007, 2005). When modelling BSMT it may be necessary to incorporate the 
time-dependent pulsatile nature of blood flow. However, the transient nature of blood side 
drug transport enables the assumption of a steady flow inlet boundary condition that in 
most cases will not have a considerable impact on WSMT. Arterial flow can be replicated by 
applying a pulsatile parabolic velocity profile at the vessels inlet. 
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5.1.2 Outlet: Pressure 
A pressure of zero can be applied to the outlet of DES computational models which reduces 
the likelihood of encountering backflow through the outlet. The application of such a 
boundary condition is prevalent in mass transport studies of this nature (Kolachalama et al., 
2009; Balakrishnan et al., 2008, 2007, 2005; Rajamohan et al., 2006). 
5.1.3 Lumen-wall interface: No-slip 
The no-slip boundary condition is standard for a model with a stationary wall and states that 
the velocity of the fluid is zero relative to the boundary (O’Brien et al., 2005; Walsh et al., 2003). 
5.1.4 Axial-symmetry 
Due to the idealised nature of some arterial computational models the use of an axial-
symmetry boundary condition can greatly reduce the number of degrees of freedom that need 
to be solved for. This will reduce the computational demand without having to sacrifice the 
accuracy of the analysis. The Reynolds number for blood flow in DES computational models is 
normally small (Re<100), indicating laminar flow and as such the application of the axial-
symmetry boundary condition should not influence the fluid flow solution. 
5.2 Application of mass transport boundary conditions 
5.2.1 Luminal inlet: Concentration 
Because mass transport within the artery’s lumen is convection dominated, it would be 
virtually impossible for drugs to diffuse in the direction opposing blood flow. Therefore it 
can be assumed that the luminal inlet concentration has a constant value equal to zero. This 
boundary condition has been used extensively in mass transport studies on DES 
(Balakrishnan et al., 2008, 2007, 2005; Mongrain et al., 2007, 2005). 
5.2.2 Luminal outlet: Convective flux 
A convective flux outflow condition is generally imposed on the outlet of a models lumen, 
resulting in a zero concentration gradient at the outlet. This boundary condition assumes 
that all the mass passing through the boundary is convection dominated. 
5.2.3 Lumen-stent-wall interface: Continuity 
A common assumption for DES mass transport studies is that the intimal layers of the artery 
are denuded and that the stent is in direct contact with the medial layer of the artery wall 
(Kolachalama et al., 2009; Balakrishnan et al., 2008, 2007, 2005; Mongrain et al., 2007, 2005). 
This negates the need to model the endothelial, intima and internal elastic lamina layers. 
Regardless of the inclusion or exclusion of these layers the continuity equation should be the 
default setting for all interior boundaries. This condition states that in the absence of sources 
or sinks, the flux in the normal direction is continuous across the boundary, i.e. the 
concentration is equal on both sides of the boundary. 
5.2.4 External faces: Insulation/symmetry 
This condition is specified at the perivascular wall and at the up- and down-stream wall 
boundaries, which should be a sufficient distance away from the stent. It specifies where the 
domain is well insulated or it can reduce the size of a model by taking advantage of 
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symmetry. Intuitively this condition states that the gradient across the boundary must be 
zero, therefore it is impermeable to mass transport. 
6. Experimental validation of mass transport behaviour 
Historically, experimental validations have been necessary to prove researchers hypotheses 
across all paradigms of science. In order to validate a theory one must not only be mindful 
of their goal but also their ability to achieve it. For instance, trying to validate a 
computational DES model using excised arterial DES would be nice in theory but in practice 
may prove fruitless because it would be near impossible to obtain the site specific drug 
concentrations within the artery wall, necessary for the researcher to examine the nuances of 
stent design that they are interested in analysing. It is often useful to validate a single aspect 
of the model if possible. With regards to DES, a solitary WSMT model may be acceptable,as 
a vast body of knowledge pertaining to fluid flow problems already exists, unlike the as of 
yet mature understanding of WSMT and how the behaviour of the porous artery wall and 
other pertinent features influence the mass transport therein. 
Figure 3 illustrates an example of a validation flowchart for a study of mass transport from 
DES. The first process in designing a validation experiment is to analyse the problem as a 
whole and see what you would like to prove. Then certain aspects of the problem that are 
relatively rudimentary can be neglected from the validation, providing they won’t have a 
fundamental impact on the outcome of the test. The flowchart is divided up into two 
streams that are developed jointly in order to achieve a desired validation. The experimental 
mass transport validation is on the left and the development of the corresponding 
computational mass transport model is on the right. In both streams BSMT is not 
highlighted for inclusion in this example’s validation procedure. This may be due to the 
readily available examples of validations of this nature in literature or its minimal impact on 
the outcome of the results. This study was designed to investigate instances of WSMT in 
relation to DES design and deployment. 
How accurate do you want your computational model to be and what assumptions are 
going to be made? The flowchart (Figure 3) describing this example validation decided to 
neglect convection-diffusion mass transport in the artery wall and concentrate on validating 
a diffusion only model. The reason for such a decision could be threefold; 1) an artery 
requiring a DES would be highly calcified and therefore the plaque can act as a buffer to 
stop or considerably reduce the flow in the porous wall, 2) an analysis of the Peclet number 
(equation 8) demonstrates diffusion dominated transport for a give drug or 3) the inability 
to create and obtain tangible results from an applicable experimental model with both 
convection and diffusion. The next aspect of the computational model is the characterisation 
of the artery wall, i.e. should it be modelled as a porous medium. Although flow in the wall 
has been neglected the application of a porous wall still can have a bearing on the outcome 
of mass transport due to the characterisation of the effective diffusivity and its propensity to 
change under varying stenting conditions (equation 12). 
In this example a computational model has been identified in which many of the aspects of 
the in vivo stenting conditions remain but more importantly contains the ability to develop 
and analyse a corresponding experimental validation. Validations of this nature are a 
powerful tool in a researchers arsenal because once the initial hypotheses has been validated 
the computational model can be changed to any geometry imaginable to create more 
realistic stenting scenarios, and when solving the problem using the same physics one can 
have full confidence in the results. 
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Fig. 3. Flowchart demonstrating the process of identifying an appropriate route for the 
experimental validation of DES mass transport. 
6.1 Historical experimental mass transport validations 
Experimental techniques to simulate mass transport in the vasculature have been an integral 
part in the development of DES. Various techniques can be applied depending on the 
required outcome from the analysis. For example if lumen transport is to be analysed a 
common approach would be to introduce a dye to a flowing system. Concentrations are 
then measured at certain time points and locations by withdrawing fluid samples so that the 
optical dye intensity can be determined.  
Markou et al. (1998) employed this approach when analysing the local transport of anti-
restenotic agents from a novel drug delivery device. The device consisted of a porous 
membrane that lined the artery wall and was the location where drugs would be infused into 
the artery. Their experimental approach consisted of a simulated artery section with a 1cm slit 
around its circumference. Dye was then infused from this slit in a radial direction into the 
lumen at uniform speed. It was found that the radial diffusion of the species was minimal in 
comparison to the axial convection therefore the majority of species remain in close proximity 
to the wall. This experiment was validated with the commercially available finite volume 
solver Fluent (Lebanon, NH). The computational models predicted an increase in dye 
concentration at the wall with an increase in the infusion rate. The same effect was witnessed 
experimentally and there was good agreement between the results. This study indicates the 
dominance of convective transport over diffusive transport in the arteries lumen. 
Lutostansky et al. (2003) adopted a similar technique when conducting an experimental 
analysis of mass transport in the recirculation region downstream of a sudden expansion. Dye 
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concentrations were determined at four equidistant locations after the sudden expansion. 
Experimental concentrations were taken over the course of one hour and showed very good 
correlation with predicted results from two numerical codes, the finite volume code Fluent 
(Lebanon, NH) and a finite element code FTSP (developed by Graz University of Technology). 
Although these experiments provided a validation of their numerical approach, they are 
limited in that they cannot be used to analyse mass transport within a porous wall. 
In 2001, Hwang et al. found that stent based delivery, from a Palmaz-Schatz Crown stent 
(Cordis), resulted in large variations in concentration gradients. Drug concentrations were 
found to vary from zero to several times the mean over a few micrometres. The 
aforementioned stents were spray coated with a fluorescein sodium/ethylene vinyl acetate 
copolymer and deployed in excised bovine carotid arteries. The arteries were positioned in 
an ex vivo perfusion apparatus and immersed in a perivascular bath where coronary flow 
was simulated. After 3 hours the arteries were removed and cut into slices. The fluorescein 
concentration was then measured with a spectrofluorometer. Although the experiment was 
not used to validate a computational model, the effects witnessed experimentally were 
compared to variations in simulated drug physicochemical properties. They concluded that 
the proximity of the device does not necessarily ensure adequate targeting because transport 
forces can cause local concentrations to deviate from the mean concentration.  
In a later paper Hwang et al. (2005) evaluated the paclitaxel uptake in stented abdominal 
aortas of adult male Sprague-Dawley rats in the presence and absence of controlled mural 
thrombus. The in vivo clot dimensions were determined and used as boundary conditions 
and input parameters for the computational model. The computational analysis predicted 
an arterial drug ratio of 0.56 which correlates with the 50% decrease in arterial uptake 
ascertained from the animal experiments. Hwang et al. (2005) discovered that by varying 
clot size and location, large variations in arterial uptake were witnessed. 
In 2007, Balakrishnan et al. deployed a Cypher sirolimus eluting stents in porcine arteries. At 
the desired time points of 1, 8, 14, 30, 60 and 90 days after implantation the stents were 
harvested and analysed. In each case the stents were carefully removed from the artery and 
the remaining drug within the polymer was determined. When subtracted from the amount of 
drug prior to implantation the release fraction can be calculated. At each time point this 
fractional drug release was compared to numerical predictions using Fluent (Lebanon, NH). A 
good correlation validated the Fickian diffusion analysis applied with the numerical solver to 
approximate the drug transport from the coating. However, validating drug release from the 
polymer coating does not elucidate subsequent drug uptake within the porous artery wall. 
In 2010, O’Connell and Walsh developed an analogous model of artery wall mass transport, 
examining the hypothesis of how compression of a porous media alters mass transport within. 
Due to the difficulty in measuring site specific concentrations within the artery wall they 
developed a scaled up experiment. It consisted of a bed of pH paper that was saturated in a 
neutral pH solution in order to fill the pore space of the material, similar to that of the artery 
walls interstitial fluid. The wall is then compressed, in increments up to a maximum of 23.75% 
of its initial thickness, and then the species of interest, an acid of pH 2.0, is introduced to the 
system and the resulting colour change was used as a marker for concentration. This enabled 
the site specific measurement of concentration at different depths throughout the porous wall. 
These experimental results were then validated computationally using the finite element 
solver COMSOL Multiphysics. The authors concluded that compression of a porous artery 
wall contributes significantly to the modulation of arterial WSMT and should be considered in 
future DES computational studies. 
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7. Computational modelling of mass transport from drug eluting stents 
The following computational models were created to illustrate how changes in stenting 
deployment conditions can influence drug concentrations within the artery wall, analysed 
after 30 and 60 minutes for each model. Figure 4 describes the five 2-D axis-symmetric 
computational models that were analysed. Model 1 in figure 4 depicts the locations of drug 
concentration measurement through the depth of the artery wall and axially down the 
artery at a depth of 25% and 50% of the wall thickness (WT) beneath the strut. The models 
are described as follows: 
Model 1. In the absence of a lumen and subsequent BSMT, this model only considered 
WSMT from a single DES stent strut (150µm) deployed flush against a single layer artery 
wall (200µm). In this instance WSMT is purely diffusive. 
Model 2. Similar to Model 1 but with the inclusion of a steady blood flow profile (mean 
velocity = 0.1m/s) through the arterial lumen. Here WSMT is purely diffusive and BSMT is 
modelled using the convection-diffusion equation. 
Model 3. Similar to Model 2 but with the inclusion of a 20µm thick layer of plaque along the 
artery wall. 
Model 4. Similar to Model 2 only the stent strut becomes embedded in the artery wall as it 
compresses it by 25% of the wall thickness. 
Model 5. Similar to Model 4 except upon compression of the wall the stent strut doesn’t 
become embedded. 
A hypothetical drug was used in the analysis with effective diffusivity values in each 
respective media defined in table 1. It is the combination of both the drug used and the 
characteristics of the media within which transport takes place that determines the effective 
diffusivity value. This fact becomes evident as the effective diffusivity of the drug in the 
compressed wall is determined. The drug remains the same but, as described in equation 12, 
changes to the tortuosity (Ǖ) and porosity (ε) of the wall alters the effective diffusivity within. 
From equation 15 the pore path (L) remains the same length but the distance (X) has reduced 
due to the 25% compression of the artery wall. Therefore the tortuosity of the compressed wall 
(ǕCW) can be described as a function of the tortuosity of the wall in its original state (ǕW). 
1.333 1.333
0.75
CW W
L L
X X
τ τ= = =  
Similarly, as the wall is compressed the total volume and pore volume of the wall under 
compression reduces but the fibre volume remains the same. To this end εCW= 0.787εW and 
the effective diffusivity of the compressed wall (DCW) can be described as follows: 
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Diffusivity in Lumen DL = 1×10-10 m2/s 
Diffusivity in Stent Coating DS = 1×10-14 m2/s 
Diffusivity in Plaque DP = 1×10-13 m2/s 
Diffusivity in Wall DW = 1×10-12 m2/s 
Diffusivity in Compressed Wall DCW = 0.59×10-12 m2/s 
Table 1. Effective diffusivity values of the different layers of arterial DES models. 
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Fig. 4. Illustration of 2-D axis-symmetric computational models used in the DES mass 
transport analysis and their resulting drug concentration contours after 30 minutes. 
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7.1 Computational predictions of mass transport in the artery wall 
Even though BSMT doesn’t significantly contribute to the distal absorption of drugs into 
the artery wall, it is a necessary element of the modelling process as it provides a more 
realistic representation of how the drugs in the DES dissipate in the vasculature. Failure to 
model BSMT (Model 1) culminates in the entire reservoir of antirestenotic drug, from both 
the luminal and abluminal side of the stent, having no choice but to eventually transport 
into the wall. This as we know is not the case as a considerable amount of drug is lost to 
the blood stream. Figures 5-7 demonstrate that for both time points and at each location 
the drug concentration for Model 1 is greater than that of Model 2 due to the absence of 
BSMT. Model 3 examined the influence of arterial plaque, which was given a drug 
diffusivity of 1×10-13m2/s. In reality plaque size and composition will vary from patient to 
patient and the implication of this is a study in itself where a range of plaque types would 
need to be modelled in order to quantitatively predict its influence on WSMT. For the 
purpose of demonstrating the influence that the presence of any plaque may have on mass 
transport, a drug diffusivity was chosen that is an order of magnitude between the 
diffusivities in the DES coating and the uncompressed artery wall respectively. What 
Model 3 demonstrates is that even a 20µm thick layer of plaque between the stent and the 
artery wall can significantly reduce uptake within the artery wall, even more so than 
arterial compression. 
 
 
 
 
Fig. 5. Drug concentrations through the depth of the artery wall, as illustrated in Fig 4 
Model 1. Concentrations are measured after 30 minutes (solid line) and 60 minutes (dashed 
line) respectively. 
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Fig. 6. Axial drug concentrations at 25% of the artery wall depth, illustrated in Fig 4 Model 1 
by the 25% WT concentration line. Concentrations are measured after 30 minutes (solid line) 
and 60 minutes (dashed line) respectively. 
 
 
Fig. 7. Axial drug concentrations at 50% of the artery wall depth, illustrated in Fig 4 Model 1 
by the 50% WT concentration line. Concentrations are measured after 30 minutes (solid line) 
and 60 minutes (dashed line) respectively. 
www.intechopen.com
 Arterial Mass Transport Behaviour of Drugs from Drug Eluting Stents 
 
321 
The influence of compression on a porous wall in relation to mass transport has been 
demonstrated experimentally by O’Connell and Walsh (2010) and is evident in the results 
from Models 4 and 5. Histological evidence demonstrated that upon stent implantation 
some struts almost cut into the wall (Model 4) while others merely compress it providing 
gradual recovery either side of the stent strut (Model 5). Contrasting concentration profiles 
from these models elucidate to the inclusion of compression alone may not necessarily be 
adequate enough because the surrounding tissue orientation will also play a role in WSMT. 
Intuitively the greater the DES surface area in contact with arterial tissue the greater its 
ability to transport drugs into the wall. This holds true when comparing the concentration 
profiles of Models 4 and 5. The depth concentrations at the early time point for both models 
are very similar (Figure 5) but there is a notable difference in the axial concentration plots at 
both 25% and 50% of the wall thickness, whereby the 60% greater wall contact surface area 
of model 4 results in an increased concentration profile. 
8. Conclusion 
Understanding the behaviour of DES in the pursuit of improving device functionality is of 
great importance to clinicians and researchers alike. The modern application of 
computational techniques have greatly aided in achieving this goal, with researchers 
continuingly adding to the global understanding of drug mass transport from these devices. 
However, computational modelling isn’t the complete solution because exact recreation of 
DES deployment and ensuing mass transport is not feasible for a number of reasons. No two 
patients will have identical stenosis of the coronary artery and therefore a single 
computational model will not provide the information required to comprehensively assess 
the viability of a single stent design. Instead a variety of models that will cover the spectrum 
of DES deployment scenarios is required and to computationally recreate these like for like 
with in vivo stenting conditions would be too computationally demanding for the same 
rewards that one could yield with a simplified analysis. 
However, one must be mindful when simplifying the problem. The computational models 
developed in this chapter were created as 2-D axis-symmetric models as the study was 
intent on analysing the influence of relatively simple geometries. However, this may not 
always be the case and the need may arise where it would be necessary to model the 
problem in 3-D. The pitfalls of over simplification can be seen in the computational Model 1 
where failure to model BSMT results in drug concentrations that are higher than that of the 
more realistic case, Model 2, that includes the luminal blood flow and mass transport 
therein. 
Computational models where DES struts are flush against a bare artery wall have their 
merits but a greater degree of complexity needs to be implemented if an improved insight 
into DES mass transport within the coronary artery environment is to be gained. These 
arteries are heavily diseased and even a thin layer of plaque between the stent strut and the 
wall can inhibit WSMT. The compression of the porous artery wall upon stent expansion has 
an interesting effect on drug concentration within the wall. The reduction in artery wall 
diffusivity results in higher peak concentrations beneath the stent strut compared to the 
models where artery wall compression is not present. This pooling of drugs close to the 
stent strut is undesirable as it retards the early penetration of drugs into the wall, 
demonstrated in Figure 5 as the uncompressed artery wall of Model 2 recorded 
concentrations higher than that of Models 4 and 5 from a depth of approximately 50µm 
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through the rest of the artery wall. There is also the danger of potential toxicity due to 
prolonged exposure of high drug concentrations close to the strut. 
Analysis of mass transport from DES requires a multifaceted approach in order to predict 
behaviour of these devices and subsequently their response to in vivo arterial conditions. 
Future research that is mindful of preoperative DES design and postoperative 
environmental conditions will increase our knowledge of the second generation DES and 
enable us as a community to prepare for the advent of biodegradable DES. 
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